ESR1 and breast cancer: In breast cancer patients who did not receive adjuvant systemic therapy, a strong prognostic effect of a B cell metagene including IGKC was seen in patients with rapidly proliferating, node-negative, ER-positive, HER2-negative breast cancer [1].